Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial Meeting Abstract
| Authors: | Senan, S.; Spigel, D. R.; Cho, B. C.; Laktionov, K.; Zenke, Y.; Lee, K. H.; Wang, Q.; Navarro Mendivil, A. F.; Buchmeier, E. L.; Sezgin Goksu, S.; Badzio, A.; Shi, A.; Daniel, D. B.; Zemanova, M.; Iyengar, P.; Paz-Ares, L. G.; Szadkowski, L.; Chugh, P.; Lai, W. C. V.; Cheng, Y. |
| Abstract Title: | Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | 1267 |
| End Page: | 1268 |
| Language: | English |
| ACCESSION: | WOS:001326612903091 |
| DOI: | 10.1016/j.annonc.2024.08.2324 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA81 -- Source: Wos |
